Unique experiment aims to rapidly test lung cancer drugs

the ONA take:

Five drug companies, the government, private foundations, and advocacy groups have come together to try a bold new way for testing cancer drugs. Described as a medical version of speed dating, physicians will sort through multiple experimental drugs and match patients to the one most likely to succeed based on each person’s unique tumor gene profile. The goal is to speed new treatments to market and give seriously ill patients more chances to find something that will help. Patients who enroll in this umbrella study will undergo full gene testing and have access to many treatment options, as opposed to signing up for a clinical trial testing a single drug. The experiment will cost about $150 million. The National Cancer Institute is chipping in $25 million, and the rest will come from foundations, charities, and others in the partnership. Amgen, Genentech, Pfizer, AstraZeneca PLC, and AstraZeneca’s global biologics partner, MedImmune are involved in the initial round of testing. Up to 1,000 patients can be enrolled in the study per year.

Unique experiment aims to rapidly test lung cancer drugs
Unique experiment aims to rapidly test lung cancer drugs
A bold new way to test cancer drugs started Monday in hundreds of hospitals around the U.S. In a medical version of speed dating, doctors will sort through multiple experimental drugs and match patients to the one most likely to succeed based on each person's unique tumor gene profile.
READ FULL ARTICLE From St. Louis Post-Dispatch
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs